PFE6:45 AMPfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidancepfizer.com
PFE6:45 AMPfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental VitiligoTrial Results • Phase 3pfizer.com
PFE4:30 PMEuropean Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Unionpfizer.com
PFE4:30 PMFDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancerpfizer.com
PFE11:23 AMU.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibilitypfizer.com
PFE2:10 PMFDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenancepfizer.com